Edition:
United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

65.85USD
27 Feb 2017
Change (% chg)

$-0.31 (-0.47%)
Prev Close
$66.16
Open
$65.78
Day's High
$65.94
Day's Low
$65.56
Volume
7,134,489
Avg. Vol
10,969,825
52-wk High
$66.16
52-wk Low
$50.09

Latest Key Developments (Source: Significant Developments)

In first phase 3 trial Merck's virus vaccine (V2120 reduced the incidence of confirmed herpes zoster cases
Friday, 24 Feb 2017 04:00pm EST 

Merck & Co Inc : In first phase 3 trial, Merck's investigational inactivated varicella zoster virus vaccine (V212) reduced the incidence of confirmed herpes zoster cases by an estimated 64 percent in immunocompromised subjects . Merck & Co Inc - in trial, V212 met its primary endpoint . Merck & Co Inc - secondary endpoint findings from study showed that V212 reduced incidence of moderate-to-severe hz pain by an estimated 69.5 percent . Merck & Co Inc - in addition, v212 showed reduction of other hz complications by an estimated 73.5 percent . Merck & Co - in trial, V212 demonstrated an estimated 83.7 percent reduction of incidence of post-herpetic neuralgia beyond 90 days after onset of hz .Merck- look forward to exploring data further, reviewing results of additional phase 3 study that is underway in immunocompromised patients with malignancies.  Full Article

Merck to record $2.9 bln impairment charge related to uprifosbuvir program - SEC filing
Thursday, 23 Feb 2017 05:53pm EST 

Merck & Co Inc : On Feb 17, determined that it will record intangible asset impairment charge related to research program for MK-3682, uprifosbuvir - SEC filing . Company's previously reported Q4 and full year non-GAAP EPS remain unchanged - SEC filing . Continues to evaluate options with respect to uprifosbuvir clinical development program . Will monitor remaining $240 million intangible asset for further impairment . "Will monitor remaining $240 million intangible asset for further impairment" . Previously reported Q4 2016 GAAP diluted earnings per share (EPS) were reduced from $0.42 to a loss of $0.22 . $240 million fair value is to be recognized as a pre-tax impairment charge of $2.9 billion, which is to be reflected in the Co’s 2016 results .Full-year 2016 GAAP EPS were reduced from $2.04 to $1.41.  Full Article

Biothera Pharmaceuticals initiates patient dosing in phase 2 trial investigating Imprime PGG, Merck's Keytruda
Thursday, 23 Feb 2017 09:00am EST 

Merck & Co Inc : Biothera Pharmaceuticals initiates patient dosing in phase 2 trial investigating imprime pgg and merck’s keytruda® (pembrolizumab) .Biothera pharmaceuticals initiates patient dosing in phase 2 trial investigating imprime pgg and merck's keytruda® (pembrolizumab).  Full Article

Merck announces Epoch study of Verubecestat
Tuesday, 14 Feb 2017 05:00pm EST 

Merck & Co Inc : Merck announces epoch study of verubecestat for the treatment of people with mild to moderate alzheimer's disease to stop for lack of efficacy . Merck & Co Inc - apecs study in people with prodromal alzheimer's disease to continue . Merck & Co Inc - results from protocol 019 are expected in February 2019. . Merck & Co Inc - Merck is stopping epoch study following recommendation of external data monitoring committee . Merck & Co Inc says edmc noted that safety signals observed in study "are not sufficient to warrant stopping study 017" . Merck - external data monitoring committee determined that there was "virtually no chance" of finding positive clinical effect in epoch study . Merck & Co Inc says edmc recommended that protocol 019, also known as apecs, continue unchanged .Merck & Co Inc - while co is "disappointed" that a benefit was not observed in epoch study, co's work continues with apecs.  Full Article

Capital World Investors reports 5.1 pct passive stake in Merck & Co as on Dec 30 - SEC Filing
Monday, 13 Feb 2017 05:14pm EST 

Merck & Co Inc :Capital World Investors reports 5.1 percent passive stake in Merck & Co Inc as on December 30, 2016 - SEC Filing.  Full Article

Immunovaccine says Princess Margaret Cancer Centre to conduct Phase 2 clinical trial to evaluate use of co, Merck's combination of immunotherapies
Monday, 6 Feb 2017 07:05am EST 

Immunovaccine Inc : Immunovaccine's lead immuno-oncology candidate to enter investigator-sponsored Phase 2 clinical trial in ovarian cancer in combination with approved anti-PD-1 drug . Princess Margaret Cancer Centre to conduct Phase 2 clinical trial to evaluate use of combination of immunotherapies from co and Merck . Expects to announce top-line interim results for Phase 1B trial of DPX-Survivac by end of March 2017 .In addition to Phase 2 trial, Immunovaccine is conducting a phase 1B trial with Incyte Corporation.  Full Article

Merck says FDA accepts two SBLAs for Keytruda
Friday, 3 Feb 2017 06:45am EST 

Merck & Co Inc : FDA accepts two SBLAs for Merck's Keytruda® (pembrolizumab) for locally advanced or metastatic urothelial cancer in cisplatin-ineligible first-line and second-line post-platinum failure treatment settings . Merck & Co Inc - PDUFA, or target action, date for both applications is June 14, 2017 .Merck & Co Inc - Keytruda also receives breakthrough therapy designation for second-line treatment based on Keynote-045.  Full Article

FDA grants accelerated approval to Bristol-Myers Squibb's nivolumab
Thursday, 2 Feb 2017 02:33pm EST 

U.S. Food and Drug Administration:Granted accelerated approval to Bristol-Myers Squibb Company's nivolumab for treatment of locally advanced or metastatic urothelial carcinoma.  Full Article

Merck CEO says business development a priority
Thursday, 2 Feb 2017 09:11am EST 

Merck & Co Inc : Merck & Co CEO says business development a priority with focus on augmenting early and mid-stage pipeline . Merck & Co CEO says encouraged by first meeting with President Trump . Merck sees higher expenses 1H 2017 due to further Keytruda development . Merck CEO says confident Trump Administration understands challenges of drug development .Merck CEO says believes Trump focus on patients being able to afford co-pays rather than overall cost of drugs.  Full Article

Merck Q4 adjusted earnings per share $0.89
Thursday, 2 Feb 2017 06:53am EST 

Merck & Co Inc : Merck announces fourth-quarter and full-year 2016 financial results . Q4 non-GAAP earnings per share $0.89 . Q4 GAAP earnings per share $0.42 . Q4 earnings per share view $0.89 -- Thomson Reuters I/B/E/S . Q4 sales $10.1 billion versus i/b/e/s view $10.22 billion . Merck & Co Inc - Fourth-quarter pharmaceutical sales decreased 1 percent to $8.9 billion . Merck & Co Inc qtrly Keytruda sales $483 million versus $214 million . Q4 Remicade sales $269 million versus $396 million . Merck & Co Inc says Q4 Januvia/Janumet sales were $1,509 million versus $1,447 million year ago . Merck & Co - Sees 2017 worldwide sales to be between $38.6 billion and $40.1 billion, including an about 2 percent negative impact from foreign exchange . Sees FY 2017 sales $38.6 billion to $40.1 billion . Sees FY 2017 non-GAAP earnings per share $3.72 to $3.87 . Sees FY 2017 GAAP earnings per share $2.47 to $2.62 .FY 2017 earnings per share view $3.85, revenue view $40.04 billion -- Thomson Reuters I/B/E/S.  Full Article

More From Around the Web

BRIEF-In first phase 3 trial Merck's virus vaccine (V2120 reduced the incidence of confirmed herpes zoster cases

* In first phase 3 trial, Merck's investigational inactivated varicella zoster virus vaccine (V212) reduced the incidence of confirmed herpes zoster cases by an estimated 64 percent in immunocompromised subjects